Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab.
Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab.
复制标题
DOI：
10.1093/ckj/sfx001
复制
发表时间：
2017-06
影响因子：
4.6
通讯作者：
Gohh R
中科院分区：
文献类型：
--
作者：
Merhi B;Patel N;Bayliss G;Henriksen KJ;Gohh R
增殖性肾小球肾炎伴单克隆免疫球蛋白G沉积（PGNMID）是最近发现的一种天然肾脏病理实体，已在肾移植患者中得到确认，可复发或新发疾病。迄今为止，在这两个人群中都没有明确的治疗方法。在这里，我们报告了两个异体肾移植中的PGNMID病例，说明了诊断方法的挑战，并强调了利妥昔单抗治疗后异体移植的结果作为这种疾病的潜在治疗方法。
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposit (PGNMID), a recently described pathologic entity in native kidneys, has been recognized in kidney transplant patients, where it can present as either recurrent or de novo disease. There is no definitive treatment to date, in either population. Here, we present two cases of PGNMID in kidney allografts that illustrate the challenges of diagnostic approach and highlight the allograft outcome after treatment with rituximab as a potential treatment of this condition.